---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-000932"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:21:07.644269+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Genprex provides clinical trial updates for Acclaim-1, Acclaim-3, and diabetes gene therapy program

## Summary
- Acclaim-1 Phase 2a expansion enrolling; interim analysis after 19 patients expected H2 2025.
- Acclaim-3 Phase 2 expansion opened; enrollment of first 25 patients for interim analysis expected H2 2025.
- Diabetes gene therapy program licensed from Univ. of Pittsburgh; seeking FDA guidance for IND-enabling studies in H2 2025.
- Acclaim-1 has FDA Fast Track; Acclaim-3 has Fast Track and Orphan Drug designations.
- Initiated research on non-viral lipid nanoparticle delivery system for diabetes program.

## SEC filing metadata
- accession: 0001437749-25-000932
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774925000932/0001437749-25-000932-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774925000932/gnpx20250105_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-000932
- JSON: https://secwatch.observer/filing/0001437749-25-000932.json
- Plain text: https://secwatch.observer/filing/0001437749-25-000932.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.